« Return to News | Technology Solutions

PerkinElmer buys Labtronics

Monday, May 16, 2011 12:54 PM

Massachusetts-based PerkinElmer life sciences software company has bought Canada-based electronic laboratory notebook provider Labtronics, according to Fierce BiotechIT.

PerkinElmer did not disclose how much it is paying for Labtronics.

The Labtronics purchase allows PerkinElmer to extend its electronic lab notebook and data integration software product offerings. The products are used for regulated and non-regulated quality control as well as late-stage product testing or method development labs, according to PerkinElmer.

"We welcome the addition of Labtronics to PerkinElmer's growing portfolio of informatics and software solutions for laboratory environments, as we enhance the Company's strategic focus on enterprise-wide knowledge sharing and access," Dusty Tenney, PerkinElmer's president of analytical sciences and laboratory services, said in a statement. "This acquisition successfully positions PerkinElmer as the only technology provider able to deploy an optimized ELN solution across a global customer's entire value chain, from research to manufacturing."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.